| Name | Bleselumab |
|---|
| Description | Bleselumab (ASKP 1240) is a human anti-CD40 monoclonal antibody (mAb). Bleselumab binds to human CD40 with high affinity (Kd: 0.24 nM). Bleselumab inhibits immune responses by blocking the interaction of CD40 with its ligand CD40L. Bleselumab prevents organ transplant rejection[1]. |
|---|---|
| Related Catalog | |
| Target |
CD40[1] |
| In Vitro | Bleselumab (0-1 μg/mL,48 h) 剂量依赖性地抑制可溶性 CD154 诱导的 PBMCs 增殖[2]。 Cell Viability Assay[2] Cell Line: PBMCs Concentration: 0-1 μg/mL Incubation Time: 48 h Result: Inhibited PBMC proliferation induced by shCD154 in human, cynomolgus monkey and rabbit blood samples. |
| In Vivo | Bleselumab (0.1-10mg/kg,静脉注射) 抑制食蟹猴的迟发型超敏反应 (DTH)[2]。 Bleselumab (2 mg/kg,静脉注射) 可延长食蟹猴移植肾的存活时间[3]。 Bleselumab (2 或 5 mg/kg,静脉注射) 与 Tacrolimus (HY-13756) 联用显示比单一疗法更长的中位生存时间 (MST)[3]。 Animal Model: Cynomolgus monkeys[2]. Dosage: 0.1, 1 and 10 mg/kg Administration: Intravenous injection (i.v.) Result: Inhibited anti-TTx IgG and anti-TTx IgM productions in a concentration-dependent manner. |
| References |
| No Any Chemical & Physical Properties |